Sale!

Non-Invasive Prenatal Testing Yes-In-Gene Test

3,000 د.إ

-25%

Non-Invasive Prenatal Testing (NIPT), specifically the Yes-In-Gene Test, is an advanced screening method offered by DNA Labs UAE, designed to assess the risk of certain genetic conditions in a fetus. This cutting-edge test, priced at 3000 AED, is conducted through a simple blood draw from the mother, eliminating the risks associated with invasive procedures. It analyzes fragments of fetal DNA circulating in the maternal bloodstream to screen for chromosomal abnormalities such as Down syndrome, Edwards syndrome, and Patau syndrome, among others. The Yes-In-Gene Test offers expectant parents a safe, accurate, and early insight into the genetic health of their baby, providing peace of mind and valuable information for pregnancy management.

Home  Sample collection service available

  • 100% accuaret DNA Results
  • Ranked as Most trusted Genetic DNA Lab
Guaranteed Safe Checkout

Non-invasive Prenatal Testing Yes-In-Gene Test

Cost: AED 3000.0

Test Components:

Please request collection material

Price:

AED 3000.0

Sample Condition:

Peripheral blood (10ml)

Report Delivery:

10-15 days

Method:

NGS (Next Generation Sequencing)

Test Type:

Genetics

Doctor:

General Physician

Test Department:

Pre Test Information

Non-invasive Prenatal Testing (Yes-In-Gene)

Non-invasive prenatal testing (NIPT), also known as cell-free DNA testing, is a screening test used to assess the risk of certain chromosomal abnormalities in a fetus. One specific example of NIPT is the Yes-In-Gene test. The Yes-In-Gene test is a non-invasive prenatal test that analyzes the cell-free DNA fragments from the fetus that circulate in the mother’s bloodstream. It is typically performed between 9-10 weeks of pregnancy and requires a blood sample from the pregnant woman.

During pregnancy, a small amount of the fetus’s DNA is released into the mother’s bloodstream. This DNA can be analyzed to detect certain genetic conditions and chromosomal abnormalities, such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13). The Yes-In-Gene test uses advanced technology to detect and quantify the fetal DNA fragments in the mother’s blood. It then compares the amount of fetal DNA to the amount of maternal DNA to determine the risk of chromosomal abnormalities.

The test is considered non-invasive because it does not pose any risk to the fetus or the mother. It does not involve any invasive procedures, such as amniocentesis or chorionic villus sampling, which carry a small risk of miscarriage. The Yes-In-Gene test has a high accuracy rate in detecting chromosomal abnormalities, with a sensitivity of over 99% and a low false-positive rate.

However, it is important to note that NIPT is a screening test and not a diagnostic test. A positive result from the Yes-In-Gene test would typically be followed up with further diagnostic testing, such as amniocentesis or chorionic villus sampling, to confirm the results.

Overall, non-invasive prenatal testing, including the Yes-In-Gene test, has revolutionized prenatal screening by providing a safe and accurate way to assess the risk of chromosomal abnormalities in a fetus. It allows parents to make informed decisions about their pregnancy and potentially prepare for the care of a child with special needs.

Test Name Non-invasive Prenatal testing Yes-In-Gene Test
Components Please request collection material
Price 3000.0 AED
Sample Condition Peripheral blood (10ml)
Report Delivery 10-15 days
Method NGS
Test type Genetics
Doctor General Physician
Test Department:
Pre Test Information Non-invasive Prenatal testing (Yes-In-Gene) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details

Non-invasive prenatal testing (NIPT), also known as cell-free DNA testing, is a screening test used to assess the risk of certain chromosomal abnormalities in a fetus. One specific example of NIPT is the Yes-In-Gene test.

The Yes-In-Gene test is a non-invasive prenatal test that analyzes the cell-free DNA fragments from the fetus that circulate in the mother’s bloodstream. It is typically performed between 9-10 weeks of pregnancy and requires a blood sample from the pregnant woman.

During pregnancy, a small amount of the fetus’s DNA is released into the mother’s bloodstream. This DNA can be analyzed to detect certain genetic conditions and chromosomal abnormalities, such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13).

The Yes-In-Gene test uses advanced technology to detect and quantify the fetal DNA fragments in the mother’s blood. It then compares the amount of fetal DNA to the amount of maternal DNA to determine the risk of chromosomal abnormalities.

The test is considered non-invasive because it does not pose any risk to the fetus or the mother. It does not involve any invasive procedures, such as amniocentesis or chorionic villus sampling, which carry a small risk of miscarriage.

The Yes-In-Gene test has a high accuracy rate in detecting chromosomal abnormalities, with a sensitivity of over 99% and a low false-positive rate. However, it is important to note that NIPT is a screening test and not a diagnostic test. A positive result from the Yes-In-Gene test would typically be followed up with further diagnostic testing, such as amniocentesis or chorionic villus sampling, to confirm the results.

Overall, non-invasive prenatal testing, including the Yes-In-Gene test, has revolutionized prenatal screening by providing a safe and accurate way to assess the risk of chromosomal abnormalities in a fetus. It allows parents to make informed decisions about their pregnancy and potentially prepare for the care of a child with special needs.